Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models

Xiao Yu Wu(University of Toronto), Liang Shen(Shandong University of Technology), Guan Nan Wu(Nanjing Traditional Chinese Medicine Hospital), Hao Xu(Lianyungang Maternal and Children’s Hospital), Gang Li(Qiqihar Medical University), Che Chen(Gansu University of Traditional Chinese Medicine), Zhen Wu(Nanjing Traditional Chinese Medicine Hospital), Fu Kun Liu(Nanjing Traditional Chinese Medicine Hospital), Jia Yun Liu(Nanjing Traditional Chinese Medicine Hospital), Xue Quan Yao(Nanjing Traditional Chinese Medicine Hospital)
Oncotarget
November 12, 2015
Cited by 85


Related Papers